

**SUMMARY:** Apertus Pharmaceuticals applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Apertus Pharmaceuticals registration as a manufacturer of those controlled substances.

**SUPPLEMENTARY INFORMATION:**

By notice dated October 2, 2015, and published in the **Federal Register** on October 13, 2015, 80 FR 61470, Apertus Pharmaceuticals, 331 Consort Drive, Ballwin, Missouri 63011 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Apertus Pharmaceuticals to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the following basic classes of controlled substances:

| Controlled Substance               | Schedule |
|------------------------------------|----------|
| Marihuana (7360) .....             | I        |
| Tetrahydrocannabinols (7370) ..... | I        |
| Remifentanil (9739) .....          | II       |

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. In reference to drug codes 7360 marihuana and 7370 tetrahydrocannabinols the company plans to bulk manufacture both as synthetic substances. No other activity for these drug codes is authorized for this registration.

Dated: January 11, 2016.

**Louis J. Milione,**

*Deputy Assistant Administrator.*

[FR Doc. 2016-00778 Filed 1-15-16; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Manufacturer of Controlled Substances Registration: Rhodes Technologies**

**ACTION:** Notice of registration.

**SUMMARY:** Rhodes Technologies applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Rhodes Technologies registration as a manufacturer of those controlled substances.

**SUPPLEMENTARY INFORMATION:** By notice dated August 21, 2015, and published in the **Federal Register** on August 31, 2015, 80 FR 52511, Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Rhodes Technologies to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the following basic classes of controlled substances:

| Controlled substance               | Schedule |
|------------------------------------|----------|
| Tetrahydrocannabinols (7370) ..... | I        |
| Dihydromorphine (9145) .....       | I        |
| Methylphenidate (1724) .....       | II       |
| Codeine (9050) .....               | II       |
| Dihydrocodeine (9120) .....        | II       |
| Oxycodone (9143) .....             | II       |
| Hydromorphone (9150) .....         | II       |
| Hydrocodone (9193) .....           | II       |
| Levorphanol (9220) .....           | II       |
| Morphine (9300) .....              | II       |
| Oripavine (9330) .....             | II       |
| Thebaine (9333) .....              | II       |
| Oxymorphone (9652) .....           | II       |
| Noroxymorphone (9668) .....        | II       |

| Controlled substance    | Schedule |
|-------------------------|----------|
| Tapentadol (9780) ..... | II       |
| Fentanyl (9801) .....   | II       |

The company plans to manufacture the listed controlled substances in bulk for conversion and sale to dosage form manufacturers.

In reference to drug code 7370 the company plans to bulk manufacture synthetic tetrahydrocannabinols. No other activity for this drug code is authorized for this registration.

Dated: January 11, 2016.

**Louis J. Milione,**

*Deputy Assistant Administrator.*

[FR Doc. 2016-00781 Filed 1-15-16; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

[OMB Number 1121-0321]

**Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection: National Institute of Justice Compliance Testing Program**

**AGENCY:** Office of Justice Programs, Department of Justice.

**ACTION:** 60-day notice.

**SUMMARY:** The Department of Justice (DOJ), Office of Justice Programs, National Institute of Justice (NIJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

**DATES:** Comments are encouraged and will be accepted for 60 days until *March 21, 2016*.

**FOR FURTHER INFORMATION CONTACT:** If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Michael O'Shea (202) 305-7954, National Institute of Justice (NIJ), Office of Justice Programs, U.S. Department of Justice, 810 Seventh Street NW., Washington, DC 20531 or [Jamie.phillips@usdoj.gov](mailto:Jamie.phillips@usdoj.gov).

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should